Mariana Lopes1,#, Carlos Vila Nova2,3,#, Rui Caetano Oliveira3,4, Fernando Schmitt5, Fernando Mendes1,6,7,8,9,*, Diana Martins1,6,7,8
Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.074215
- 21 May 2026
Abstract Objectives: Triple-negative breast cancer (TNBC) accounts for approximately 15% of all invasive breast cancers and is characterized by aggressive behavior, limited therapeutic options, and poor clinical outcomes. Due to the absence of hormone receptors and HER2 expression, systemic treatment relies predominantly on chemotherapy, which is associated with high rates of early recurrence and mortality. Emerging evidence suggests that alterations in the microbiome can contribute to TNBC progression and influence therapeutic response, particularly affecting the efficacy of chemotherapy and immunotherapy through immune-mediated mechanisms; however, its role in TNBC remains incompletely understood. This systematic review aims to explore… More >